- Home
- TCBS vs GANX Comparison
TCBS vs GANX Comparison
Compare TCBS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- GANX
- Stock Information
- Founded
- TCBS 1934
- GANX 2017
- Country
- TCBS United States
- GANX United States
- Employees
- TCBS N/A
- GANX N/A
- Industry
- TCBS Banks
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- TCBS Finance
- GANX Health Care
- Exchange
- TCBS Nasdaq
- GANX Nasdaq
- Market Cap
- TCBS 48.7M
- GANX 53.4M
- IPO Year
- TCBS N/A
- GANX 2021
- Fundamental
- Price
- TCBS $15.98
- GANX $1.69
- Analyst Decision
- TCBS
- GANX Strong Buy
- Analyst Count
- TCBS 0
- GANX 5
- Target Price
- TCBS N/A
- GANX $8.00
- AVG Volume (30 Days)
- TCBS 3.3K
- GANX 328.9K
- Earning Date
- TCBS 08-01-2025
- GANX 08-12-2025
- Dividend Yield
- TCBS 1.01%
- GANX N/A
- EPS Growth
- TCBS N/A
- GANX N/A
- EPS
- TCBS 0.80
- GANX N/A
- Revenue
- TCBS $14,831,000.00
- GANX N/A
- Revenue This Year
- TCBS N/A
- GANX N/A
- Revenue Next Year
- TCBS N/A
- GANX N/A
- P/E Ratio
- TCBS $19.83
- GANX N/A
- Revenue Growth
- TCBS 51.57
- GANX N/A
- 52 Week Low
- TCBS $13.70
- GANX $0.95
- 52 Week High
- TCBS $19.40
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- TCBS 50.47
- GANX 54.36
- Support Level
- TCBS $15.86
- GANX $1.45
- Resistance Level
- TCBS $15.95
- GANX $2.12
- Average True Range (ATR)
- TCBS 0.06
- GANX 0.16
- MACD
- TCBS 0.01
- GANX 0.03
- Stochastic Oscillator
- TCBS 70.00
- GANX 39.44
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.